Innoviva (INVA) – Business Wire
-
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
-
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
-
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
-
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
-
Innoviva to Participate in the Cantor Global Healthcare Conference
-
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in
-
Innoviva Appoints Stephen Basso as Chief Financial Officer
-
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
-
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
-
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
-
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Innoviva Announces Retirement of Board Chairman
-
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
-
Innoviva Stock Trading Halted Today
-
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
-
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
-
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
-
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
-
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
-
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
-
Innoviva Completes Acquisition of La Jolla Pharmaceutical
-
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
-
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 millio
-
Innoviva Completes Acquisition of Entasis Therapeutics
-
Innoviva to Acquire La Jolla Pharmaceutical Company
-
Innoviva to Acquire La Jolla Pharmaceutical Company
-
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
-
Innoviva to Acquire Entasis Therapeutics
-
Innoviva Reports First Quarter 2022 Financial Results
-
Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes
-
Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes
-
Innoviva Reports Fourth Quarter 2021 Financial Results
-
Innoviva Reports Third Quarter 2021 Financial Results
-
Innoviva Reports Second Quarter 2021 Financial Results
-
Innoviva Announces Strategic Repurchase of GSK’s Equity Stake
-
Innoviva Reports First Quarter 2021 Financial Results
-
Innoviva Reports Fourth Quarter 2020 Financial Results
-
Innoviva Reports Third Quarter 2020 Financial Results
-
FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US
-
FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US
-
Innoviva Reports Second Quarter 2020 Financial Results
-
Innoviva Names Pavel Raifeld as Chief Executive Officer
-
Innoviva Reports First Quarter 2020 Financial Results
-
Innoviva Announces Change of Location of Annual Meeting of Stockholders to Be Held on April 24, 2020
-
GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
-
Innoviva Reports Fourth Quarter 2019 Financial Results
-
Innoviva Reports Third Quarter 2019 Financial Results
-
GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma
Back to INVA Stock Lookup
